ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • osteoporosis and rheumatic disease
  • osteoporosis and rheumatoid arthritis
  • Osteoporosis and rheumatoid arthritis (RA)
  • osteoporosis and risk
  • osteoporosis and risk assessment
  • osteoporosis and risk management
  • osteoporosis and safety
  • osteoporosis and scleroderma
  • osteoporosis and spine involvement
  • osteoporosis and spondylarthritis
  • Osteoporosis and strength
  • osteoporosis and surgery
  • osteoporosis and systemic lupus erythematosus (SLE)
  • osteoporosis and systemic sclerosis
  • osteoporosis and teriparatide
  • osteoporosis and therapy
  • Osteoporosis and thrombosis
  • osteoporosis and tobacco use
  • osteoporosis and trainee
  • osteoporosis and transplantation
  • osteoporosis and treatment
  • osteoporosis and treatment guidlelines
  • osteoporosis and uric acid
  • osteoporosis and utilization review
  • osteoporosis and vasculitis
  • osteoporosis and viruses
  • Osteoporosis and vitamins
  • osteoporosis and website
  • osteoporosis and women's health
  • osteoporosis and x-ray
  • osteoporosis and young adults
  • osteoprotegerin
  • osteoprotegerin and polymorphism
  • osteoprotegerin and pseudogout
  • osteoprotegerin and rheumatoid arthritis (RA)
  • Otoferlin
  • Outcome
  • Outcome measures
  • outcome measures and Autoimmune Skin Disease
  • outcome measures and cohort
  • outcome measures and Flare
  • outcome measures and lung
  • outcome measures and modified stoke ankylosing spondylitis spinal score (MSASSS)
  • outcome measures and outcomes
  • outcome measures and pain
  • outcome measures and patient
  • outcome measures and patient outcomes
  • outcome measures and patient participation
  • outcome measures and patient-reported outcome measures
  • outcome measures and pediatric medical center
  • outcome measures and pediatric rheumatology
  • outcome measures and pediatrics
  • outcome measures and physical activity
  • outcome measures and physical function
  • outcome measures and physical therapy
  • outcome measures and Plasmablasts
  • outcome measures and polychondritis
  • Outcome measures and polymyalgia rheumatica
  • outcome measures and polymyositis/dermatomyositis (PM/DM)
  • outcome measures and population studies
  • outcome measures and prognostic factors
  • outcome measures and psoriatic arthritis
  • outcome measures and pulmonary complications
  • outcome measures and qualitative
  • outcome measures and quality improvement
  • outcome measures and quality measures
  • outcome measures and quality of care
  • Outcome measures and quality of life
  • outcome measures and race/ethnicity
  • outcome measures and radiography
  • outcome measures and randomized trials
  • outcome measures and registry
  • outcome measures and remission
  • outcome measures and review
  • outcome measures and rheumatoid arthritis
  • outcome measures and rheumatoid arthritis (RA)
  • outcome measures and rheumatologic practice
  • outcome measures and risk assessment
  • outcome measures and rituximab
  • outcome measures and scleroderma
  • outcome measures and self-management
  • outcome measures and socio-economic inequities
  • outcome measures and spondylarthritis
  • Outcome measures and spondylarthropathy
  • outcome measures and states of activation
  • outcome measures and steroids
  • outcome measures and strength
  • outcome measures and surgery
  • outcome measures and synovitis
  • outcome measures and systemic lupus erythematosus (SLE)
  • outcome measures and systemic sclerosis
  • outcome measures and technology
  • outcome measures and total joint replacement
  • outcome measures and transplantation
  • outcome measures and treatment options
  • outcome measures and ultrasonography
  • outcome measures and ultrasound
  • outcome measures and uric acid
  • outcome measures and uveitis
  • outcome measures and vasculitis
  • outcome measures and vitamins
  • outcomes
  • outcomes and clinical trials
  • outcomes and hepatic disorders
  • outcomes and infection
  • outcomes and international
  • outcomes and longitudinal studies
  • outcomes and myopathy
  • outcomes and pain
  • outcomes and patient outcomes
  • outcomes and patient preferences
  • outcomes and pediatric rheumatology
  • outcomes and pediatrics
  • outcomes and phenotypes
  • outcomes and physical activity
  • outcomes and polyangiitis
  • outcomes and polymyalgia rheumatica
  • outcomes and polymyositis/dermatomyositis (PM/DM)
  • outcomes and population studies
  • outcomes and prednisolone
  • outcomes and pregnancy
  • outcomes and prevention
  • outcomes and prognostic factors
  • outcomes and prosthesis
  • outcomes and proteinuria
  • outcomes and psoriatic arthritis
  • outcomes and psychosocial
  • outcomes and qualitative
  • outcomes and quality improvement
  • outcomes and quality of life
  • outcomes and race/ethnicity
  • outcomes and registries
  • outcomes and registry
  • outcomes and rehabilitation
  • Outcomes and remission
  • outcomes and renal disease
  • outcomes and reversible cerebrovascular vasoconstriction
  • outcomes and rheumatic disease
  • outcomes and rheumatoid arthritis
  • outcomes and rheumatoid arthritis (RA)
  • outcomes and risk
  • outcomes and rituximab
  • outcomes and safety
  • outcomes and sarcoidosis
  • outcomes and shared dicision making
  • outcomes and shoulder disorders
  • outcomes and social support
  • outcomes and socio-economic inequities
  • outcomes and socioeconomic status
  • outcomes and spondylarthritis
  • outcomes and surgery
  • outcomes and synovium
  • outcomes and systemic lupus erythematosus (SLE)
  • outcomes and systemic sclerosis
  • outcomes and systemic vasculitides
  • outcomes and takayasu arteritis
  • outcomes and thrombosis
  • outcomes and tocilizumab
  • outcomes and total joint replacement
  • outcomes and treatment
  • outcomes and treatment options
  • outcomes and uric acid
  • outcomes and utilization review
  • outcomes and vasculitis
  • outcomes and vdi
  • outcomes and work
  • outreach
  • ovarian and pediatrics
  • ovarian and polymyositis
  • ovarian and rheumatoid arthritis (RA)
  • ovarian and systemic lupus erythematosus (SLE)
  • overweight
  • oxidative stress
  • P. Gingivalis
  • PAD
  • PAD and citrullination
  • PAD and rheumatoid arthritis (RA)
  • Paget's disease
  • Paget's disease and bisphosphonates
  • pah and ph
  • PAH and systemic sclerosis
  • pain
  • pain and adipocytokines
  • pain and anti-CCP antibodies
  • pain and cartilage
  • pain and Chronic pain
  • pain and Dynamic contrast-enhanced magnetic resonance imaging
  • pain and fatigue
  • pain and inflammation
  • pain and monoclonal antibodies
  • pain and mood
  • pain and pain management
  • pain and parathyroid hormone
  • pain and patient outcomes
  • pain and patient-reported outcome measures
  • pain and pediatric rheumatology
  • pain and pharmacotherapy
  • pain and phenotypes
  • Pain and physical activity
  • pain and physical examination
  • First |
  • « Previous Page
  • 41
  • 42
  • 43
  • 44
  • 45
  • [46]
  • 47
  • 48
  • 49
  • 50
  • 51
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology